Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
Axogen (NASDAQ: AXGN), a global leader in surgical solutions for peripheral nerve injuries, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, before market opening. The company will host an investment-community conference call and webcast at 8 a.m. ET on the same day. Investors can participate via phone by dialing (877) 407-0993 (toll-free) or (201) 689-8795, or listen online through the Investors page at www.axogeninc.com. A replay will be available on the company's website after the call.
Axogen (NASDAQ: AXGN), leader globale nella fornitura di soluzioni chirurgiche per infortuni ai nervi periferici, ha annunciato che pubblicherà i propri risultati finanziari del terzo trimestre 2024 giovedì 7 novembre 2024, prima dell'apertura del mercato. L'azienda ospiterà una teleconferenza e un webcast per la comunità degli investitori alle 8:00 ET nello stesso giorno. Gli investitori possono partecipare telefonando al numero (877) 407-0993 (numero verde) o (201) 689-8795, oppure ascoltare online tramite la pagina dedicata agli investitori su www.axogeninc.com. Una registrazione sarà disponibile sul sito web dell'azienda dopo la chiamata.
Axogen (NASDAQ: AXGN), líder global en soluciones quirúrgicas para lesiones de nervios periféricos, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el jueves 7 de noviembre de 2024, antes de la apertura del mercado. La empresa llevará a cabo una teleconferencia y un webcast para la comunidad de inversionistas a las 8 a.m. ET ese mismo día. Los inversionistas pueden participar por teléfono llamando al (877) 407-0993 (número gratuito) o al (201) 689-8795, o escuchar en línea a través de la página de Inversores en www.axogeninc.com. Una repetición estará disponible en el sitio web de la empresa después de la llamada.
Axogen (NASDAQ: AXGN), 말초 신경 손상을 위한 외과적 솔루션의 글로벌 선두주자는 2024년 3분기 재무 결과를 2024년 11월 7일 목요일, 시장 개장 전에 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8시 ET에 투자자 커뮤니티를 위한 전화 회의 및 웹캐스트를 개최할 예정입니다. 투자자는 (877) 407-0993(무료) 또는 (201) 689-8795로 전화하여 참여하거나 www.axogeninc.com의 투자자 페이지를 통해 온라인으로 청취할 수 있습니다. 통화 후 회사 웹사이트에서 재생이 가능합니다.
Axogen (NASDAQ: AXGN), leader mondial en solutions chirurgicales pour les blessures des nerfs périphériques, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le jeudi 7 novembre 2024, avant l'ouverture du marché. L'entreprise organisera une conférence téléphonique et un webinaire pour la communauté des investisseurs à 8h00 ET le même jour. Les investisseurs peuvent participer par téléphone en composant le (877) 407-0993 (appel gratuit) ou le (201) 689-8795, ou écouter en ligne via la page des investisseurs sur www.axogeninc.com. Un enregistrement sera disponible sur le site web de l'entreprise après l'appel.
Axogen (NASDAQ: AXGN), ein globaler Marktführer in chirurgischen Lösungen für periphere Nervenschäden, hat bekannt gegeben, dass die finanziellen Ergebnisse des dritten Quartals 2024 am Donnerstag, dem 7. November 2024, vor Markteröffnung veröffentlicht werden. Das Unternehmen wird am selben Tag um 8 Uhr ET eine Telefonkonferenz und einen Webcast für die Investmentgemeinschaft veranstalten. Investoren können telefonisch teilnehmen, indem sie (877) 407-0993 (gebührenfrei) oder (201) 689-8795 wählen, oder online über die Investoren-Seite unter www.axogeninc.com zuhören. Eine Wiederholung wird nach dem Anruf auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
ALACHUA, Fla. and TAMPA, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company's website at www.axogeninc.com and clicking on the webcast link.
Following the conference call, a replay will be available in the Investors section of the company's website at www.axogeninc.com.
About Axogen
Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products used across various applications and surgical specialties, including traumatic injuries, oral and maxillofacial surgery, breast reconstruction, and the surgical treatment of pain. These applications encompass both scheduled and emergent procedures. Specifically, scheduled procedures are often pursued by patients seeking relief from conditions caused by a nerve defect or previous surgical interventions. Such procedures include providing sensation for women undergoing breast reconstruction following a mastectomy, nerve reconstruction after the surgical removal of painful neuromas, and oral and maxillofacial procedures, as well as nerve decompression. Conversely, emergent procedures typically arise from injuries that initially present in an emergency room, with specialists intervening either immediately or within a few days following the initial injury. This broad range of applications underscores Axogen’s vital role in addressing diverse patient needs in peripheral nerve repair. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft®, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; Avive+ Soft Tissue Matrix™, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue repair; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international markets.
For more information, visit www.axogeninc.com
Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com
FAQ
When will Axogen (AXGN) report Q3 2024 earnings?
How can I join Axogen's (AXGN) Q3 2024 earnings call?